CIP2A is a target of bortezomib in human triple negative breast cancer cells
Breast Cancer Research, 04/30/2012Tseng LM et al.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a major determinant mediating bortezomib–induced apoptosis in triple negative breast cancer (TNBC) cells. CIP2A may thus be a potential therapeutic target in TNBC.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.